Equity / Investment · Africa · Announced 8 Jul 2026

Natco Pharma → Adcock Ingram

Natco Pharma's board approved about US$260 million for South Africa: raising its Adcock Ingram stake from 35.75% to 49% at ZAR 92.50 a share and injecting about US$146 million into its local subsidiary.

Parties: Natco Pharma (India) → Adcock Ingram (South Africa)

Value
$260m
Territory
South Africa and wider African markets
Therapeutic area
Multi-therapy
Asset
Adcock Ingram shares
Announced
8 Jul 2026

Our analysis

Why this matters

On 8 July 2026, Natco Pharma's board approved buying 19,618,825 more shares in JSE-listed Adcock Ingram at ZAR 92.50 a share (about ZAR 1.81 billion, roughly US$112 million), lifting its stake from 35.75% to 49%. It also approved investing up to INR 1,400 crore (about US$146 million) in its wholly owned subsidiary Natco Pharma South Africa. The combined commitment is about INR 25 billion (US$260 million). Closing was expected by the end of July 2026, subject to regulatory approvals.

Natco reports that Adcock Ingram generated US$423 million in revenue and about US$59 million in EBITDA in the nine months to 31 March 2026.

The full analysis is free to read with a work email on this page.

Source: Ecofin Agency

Latest deals

All Africa deals → · All equity / investment deals → · Browse all emerging-market pharma deals →